Equity alert: rosen law firm announces investigation of securities claims against acorda therapeutics, inc. – acor

New york--(business wire)--rosen law firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of acorda therapeutics, inc. (nasdaq:acor) resulting from allegations that acorda may have issued materially misleading business information to the investing public. on november 15, 2017, acorda disclosed that “it has increased the frequency of blood cell count monitoring for participants to weekly in its phase 3 program of tozadenant for parkinson’s disease...in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death.” acorda further disclosed that “[t]here have been seven cases of sepsis, all in the tozadenant groups, five of which were fatal.” on this news, shares of acorda fell $11.20 per share or over 39% from its previous closing price to close at $17.00 per share on november 15, 2017. rosen law firm is preparing a class action lawsuit to recover losses suffered by acorda investors. if you purchased shares of acorda, please visit the firm’s website at http://www.rosenlegal.com/cases-1242.html for more information. you may also contact phillip kim or kevin chan of rosen law firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com. follow us for updates on linkedin: https://www.linkedin.com/company/the-rosen-law-firm or on twitter: https://twitter.com/rosen_firm. rosen law firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. since 2014, rosen law firm has been ranked #2 in the nation by institutional shareholder services for the number of securities class action settlements annually obtained for investors. attorney advertising. prior results do not guarantee a similar outcome.
ACOR Ratings Summary
ACOR Quant Ranking